Intrepid Trial

Sponsor: The Cleveland Clinic

Sponsor Linkhttps://clinicaltrials.gov/ct2/show/NCT02291419

Study Overview: An Open label, randomized study to determine the rate of cardiovascular events at 1 year for patients with elevated troponins post major non-cardiac surgery and the impact of ticagrelor versus aspirin on the occurrence of cardiovascular events.

Target Population: Patients with severe aortic stenosis

Study Status: Actively recruiting patients

Study Website Linkhttps://clinicaltrials.gov/ct2/show/NCT02291419

Principal InvestigatorDr. Francisco Fuentes

To obtain more information, please contact the research staff at: 713-500-8828

SAPPHIRE

Sponsor: Cordis

Study Overview: The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease. This a post-market registry study that will allow Cordis, the manufacturer of the Cordis PRECISE Nitinol Stent System and the Cordis ANGIOGUARD XP/RX Emboli Capture Guidewire (ECGW) and next generation Cordis carotid stents and EPDs devices as they become commercially available to collect information about the stent and distal protection and the patients who are treated with it. The ECGW is a tiny filter basket at the end of the Guidewire in the shape of an umbrella intended to capture debris that might be released during the procedure and help reduce the chance of stroke.

Target Population: Patients with obstructive carotid artery disease receiving a Cordis stent system

Study Status: Actively recruiting patients

Study Website Linkhttp://clinicaltrials.gov/ct2/show/NCT00403078

Principal Investigator: Dr. Richard Smalling

To obtain more information, please contact the research staff at: 713-500-8828

REGULATE-PCI

Sponsor: Regado Biosciences, Inc

Sponsor Linkhttp://www.astrazeneca.com/Research

Study Overview: The REGULATE-PCI  study will evaluate the safety and efficacy of the REG1 anticoagulation system compared to bivalirudin in patients with coronary artery disease (CAD) undergoing Percutaneous Coronary Intervention (PCI) for preventing the composite of death, nonfatal infarction, nonfatal stroke and urgent target lesion revascularization (TLR) through day three.

Target Population: Patients with Coronary Artery Disease (CAD) undergoing a Percutaneous Coronary Intervention (PCI)

Study Status: Enrollment is closed

Study Website Linkhttp://clinicaltrials.gov/show/NCT01848106

Principal Investigator: Dr. Prakash Balan

To obtain more information, please contact the research staff at: 713-500-8828